Cancer Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Acute Myeloid Leukemia
Investigators at INSERM release new data on acute myeloid leukemia
April 22nd, 2008
According to recent research from Paris, France, "Chemotherapeutic drug efflux via the P-glycoprotein (P-gp) transporter encoded by the MDRI/ABCBI gene is a significant cause of drug resistance in numerous malignancies, including acute leukemias, especially in older patients with acute myeloid leukemia (AML). Therefore, the P-gp modulators that block P-gp-mediated drug efflux have been developed, and used in combination with standard chemotherapy." "In this paper, the capacity of zosuquidar, a specific P-gp modulator, to reverse chemoresistance was examined in both leukemia cell lines and primary AML blasts. The transporter protein expressions were analyzed by flow...
Source: Cancer Weekly (2008-04-22)
|
